201 related articles for article (PubMed ID: 18297267)
1. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy.
Langgartner J; Vasold A; Glück T; Reng M; Kees F
Intensive Care Med; 2008 Jun; 34(6):1091-6. PubMed ID: 18297267
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
[TBL] [Abstract][Full Text] [Related]
4. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
Zhao HY; Gu J; Lyu J; Liu D; Wang YT; Liu F; Zhu FX; An YZ
Chin Med J (Engl); 2017 May; 130(10):1139-1145. PubMed ID: 28485312
[TBL] [Abstract][Full Text] [Related]
6. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
Seyler L; Cotton F; Taccone FS; De Backer D; Macours P; Vincent JL; Jacobs F
Crit Care; 2011; 15(3):R137. PubMed ID: 21649882
[TBL] [Abstract][Full Text] [Related]
7. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?
Varghese JM; Jarrett P; Wallis SC; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
J Antimicrob Chemother; 2015 Feb; 70(2):528-33. PubMed ID: 25336163
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of meropenem in critically ill patients with severe infections.
Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
[TBL] [Abstract][Full Text] [Related]
9. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.
Chytra I; Stepan M; Benes J; Pelnar P; Zidkova A; Bergerova T; Pradl R; Kasal E
Crit Care; 2012 Jun; 16(3):R113. PubMed ID: 22742765
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations.
Nehus EJ; Mizuno T; Cox S; Goldstein SL; Vinks AA
J Clin Pharmacol; 2016 Mar; 56(3):291-7. PubMed ID: 26222329
[TBL] [Abstract][Full Text] [Related]
11. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion versus intermittent administration of meropenem in critically ill patients.
Thalhammer F; Traunmüller F; El Menyawi I; Frass M; Hollenstein UM; Locker GJ; Stoiser B; Staudinger T; Thalhammer-Scherrer R; Burgmann H
J Antimicrob Chemother; 1999 Apr; 43(4):523-7. PubMed ID: 10350382
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
Peng Y; Cheng Z; Xie F
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
Giles LJ; Jennings AC; Thomson AH; Creed G; Beale RJ; McLuckie A
Crit Care Med; 2000 Mar; 28(3):632-7. PubMed ID: 10752806
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.
Jaruratanasirikul S; Sriwiriyajan S
J Antimicrob Chemother; 2003 Sep; 52(3):518-21. PubMed ID: 12917242
[TBL] [Abstract][Full Text] [Related]
17. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.
Ulldemolins M; Vaquer S; Llauradó-Serra M; Pontes C; Calvo G; Soy D; Martín-Loeches I
Crit Care; 2014 Jun; 18(3):227. PubMed ID: 25042938
[TBL] [Abstract][Full Text] [Related]
18. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
[TBL] [Abstract][Full Text] [Related]
19. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
Cheatham SC; Kays MB; Smith DW; Wack MF; Sowinski KM
Pharmacotherapy; 2008 Jun; 28(6):691-8. PubMed ID: 18503396
[TBL] [Abstract][Full Text] [Related]
20. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
